Botulinum neurotoxin for treating tics and obsessive compulsive behaviors

Details for Australian Patent Application No. 2004233821 (hide)

Owner Allergan, Inc.

Inventors Ackerman, Alan H.

Agent Davies Collison Cave

Pub. Number AU-B-2004233821

PCT Pub. Number WO2004/096269

Priority 10/423,380 25.04.03 US; 10/424,050 25.04.03 US; 10/423,384 25.04.03 US; 10/424,009 25.04.03 US; 10/423,778 25.04.03 US

Filing date 16 April 2004

Wipo publication date 11 November 2004

Acceptance publication date 2 June 2011

International Classifications

A61K 38/48 (2006.01) Medicinal preparations containing peptides

A61P 3/10 (2006.01) Drugs for disorders of the metabolism

A61P 21/00 (2006.01) Drugs for disorders of the muscular or neuromuscular system

A61P 25/00 (2006.01) Drugs for disorders of the nervous system

A61P 27/00 (2006.01) Drugs for disorders of the senses

A61K 38/12 (2006.01) Medicinal preparations containing peptides - Cyclic peptides

Event Publications

17 November 2005 PCT application entered the National Phase

  PCT publication WO2004/096269 Priority application(s): WO2004/096269

2 June 2011 Application Accepted

  Published as AU-B-2004233821

29 September 2011 Standard Patent Sealed

Legal

The information provided by the Site not in the nature of legal or other professional advice. The information provided by the Site is derived from third parties and may contain errors. You must make your own enquiries and seek independent advice from the relevant industry professionals before acting or relying on any information contained herein. Check the above data against the Australian Patent Office AUSPAT database.

Next and Previous Patents/Applications

2004233823-Beverages containing water-soluble vitamin E

2004233809-Minimally invasive instruments for preparing vertebral endplates